Literature DB >> 11369627

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

J Storek1, M A Dawson, B Storer, T Stevens-Ayers, D G Maloney, K A Marr, R P Witherspoon, W Bensinger, M E Flowers, P Martin, R Storb, F R Appelbaum, M Boeckh.   

Abstract

Allogeneic peripheral blood stem cell grafts contain about 10 times more T and B cells than marrow grafts. Because these cells may survive in transplant recipients for a long time, recipients of blood stem cells may be less immunocompromised than recipients of marrow. Immune reconstitution was studied in 115 patients randomly assigned to receive either allogeneic marrow or filgrastim-mobilized blood stem cell transplantation. Between day 30 and 365 after transplantation, counts of most lymphocyte subsets were higher in the blood stem cell recipients. The difference was most striking for CD4 T cells (about 4-fold higher counts for CD45RA(high) CD4 T cells and about 2-fold higher counts for CD45RA(low/-)CD4 T cells; P <.05). On assessment using phytohemagglutinin and herpesvirus antigen-stimulated proliferation, T cells in the 2 groups of patients appeared equally functional. Median serum IgG levels were similar in the 2 groups. The rate of definite infections after engraftment was 1.7-fold higher in marrow recipients (P =.001). The rate of severe (inpatient treatment required) definite infections after engraftment was 2.4-fold higher in marrow recipients (P =.002). The difference in the rates of definite infections was greatest for fungal infections, intermediate for bacterial infections, and lowest for viral infections. Death associated with a fungal or bacterial infection occurred between day 30 and day 365 after transplantation in 9 marrow recipients and no blood stem cell recipients (P =.008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369627     DOI: 10.1182/blood.v97.11.3380

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  82 in total

1.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

4.  Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Authors:  Dorothea Evers; Jaap Jan Zwaginga; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

5.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

6.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

7.  Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Hirotaka Takasaki; Ayumi Numata; Satomi Ito; Reina Watanabe; Rie Hyo; Rika Ohshima; Maki Hagihara; Rika Sakai; Shin Fujisawa; Naoto Tomita; Hiroyuki Fujita; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2011-02-18       Impact factor: 2.490

8.  Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.

Authors:  Raphael Itzykson; Marie Robin; Helene Moins-Teisserenc; Marc Delord; Marc Busson; Aliénor Xhaard; Flore Sicre de Fontebrune; Régis Peffault de Latour; Antoine Toubert; Gérard Socié
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

9.  Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

Authors:  Hirohisa Nakamae; Barry E Storer; Rainer Storb; Jan Storek; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; James C Wade; Michael B Maris; Benedetto Bruno; Jens Panse; Effie Petersdorf; Ann Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-10       Impact factor: 5.742

10.  Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Maxim Norkin; Bronwen E Shaw; Ruta Brazauskas; Heather R Tecca; Helen L Leather; Juan Gea-Banacloche; Rammurti T Kamble; Zachariah DeFilipp; David A Jacobsohn; Olle Ringden; Yoshihiro Inamoto; Kimberly A Kasow; David Buchbinder; Peter Shaw; Peiman Hematti; Raquel Schears; Sherif M Badawy; Hillard M Lazarus; Neel Bhatt; Biljana Horn; Saurabh Chhabra; Kristin M Page; Betty Hamilton; Gerhard C Hildebrandt; Jean A Yared; Vaibhav Agrawal; Amer M Beitinjaneh; Navneet Majhail; Tamila Kindwall-Keller; Richard F Olsson; Helene Schoemans; Robert Peter Gale; Siddhartha Ganguly; Ibrahim A Ahmed; Harry C Schouten; Jane L Liesveld; Nandita Khera; Amir Steinberg; Ami J Shah; Melhem Solh; David I Marks; Witold Rybka; Mahmoud Aljurf; Andrew C Dietz; Usama Gergis; Biju George; Sachiko Seo; Mary E D Flowers; Minoo Battiwalla; Bipin N Savani; Marcie L Riches; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.